Endocyte Inc.
PROXY CORNER: Endocyte Inc.
May 12, 2012
West Lafayette-based Endocyte Inc. is a biopharmaceutical company developing therapies for the treatment of cancer and inflammatory
diseases.
MoreEndocyte pulls trigger on European drug submission
March 13, 2012
J.K. WallEndocyte Inc. will submit its ovarian cancer drug EC145 for European market approval in the third quarter of this year after
the European Commission granted it orphan drug status.
MoreEndocyte stays course despite being battered by investors
December 31, 2011
J.K. WallAfter spending most of 2011 as a Wall Street darling, the year ended ugly for Endocyte Inc. But CEO Ron Ellis thinks the West
Lafayette-based drug developer is in better position than ever.
MoreCancer-drug firm Endocyte to build commercial team in Indianapolis
November 12, 2011
J.K. WallEndocyte employs 12 people in Indianapolis and plans to add three or four more commercial executives there over the next year
and a half as it anticipates approval of its ovarian cancer medication in Europe.
MoreDrug shortages hit Lilly, Endocyte
November 7, 2011
J.K. WallThe nation’s shortage of certain drugs is threatening to affect research trials being conducted by Eli Lilly and Co.
and Endocyte Inc.
MoreEndocyte's potential enthralls investors
May 7, 2011
Chris O'MalleyShares of Endocyte Inc. have doubled since the company’s initial public offering in February—even though the common
wisdom is it won’t see sales from its first cancer drug until 2014.
MorePROXY CORNER: Endocyte Inc.
April 30, 2011
IBJ StaffWest Lafayette-based Endocyte Inc. is a biopharmaceutical company developing therapies for the treatment of cancer and inflammatory
diseases.
MoreRepeated price cuts take glow off Endocyte IPO
February 12, 2011
Greg AndrewsNew investors got in for $6 a share—which is less than the average price paid by prior investors, a regulatory filing
reveals.
MoreEndocyte prices IPO stock
January 14, 2011
J.K. WallThe West Lafayette-based drug development firm intends to sell 6.15 million shares for $13 to $15 apiece. That would fetch
$80 million to $92 million.
MoreEndocyte's $86M IPO plan a boon for Indiana, investors
August 28, 2010
Greg AndrewsVenture capitalists in Indiana and nationally have thrown money at the company with abandon. Local investors include CID Capital,
Clarian Health Ventures and the Indiana Future Fund.
MoreCancer drug developer Endocyte files for IPO
August 18, 2010
Scott OlsonThe company, headquartered at Purdue Research Park, said the number of shares to be offered and their price range have yet
to be determined.
MoreHealth care venture capital swoons in Indy, holds steady statewide
February 6, 2010
IBJ StaffThe uncertainty of health care reform and a bad economy curtailed venture capital flow in 2009.
MoreEndocyte, Purdue develop prostate cancer treatment device
July 13, 2009
IBJ StaffPurdue University researcher Philip Low, also the chief science officer for West Lafayette-based Endocyte Inc., has developed
a prostate cancer “homing device” to help anti-cancer agents specifically target prostate
cancer tumors.
MoreSponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
IBJ Featured Advertisers
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
graham. they are even better w/ roasted marshmallows and melted chocolate
Apparently ticket sales are slow too...mas emails have been sent by the speedway in a last ditch attempt to get place fans to come.
Garden Valley Veggie flavor Wheat Thins Toasted Chips. Don't judge until you try them, haters!
Doc, a few important errors in your statements:
(1) The developer is spending the CITY'S money (the city is paying for the cost of the garage), so the city can damn well insist on a quality design.
(2) The LAW requires the proposed building to comply with design standards, and insisting that people follow the law is not giving anyone the "run-around."
(3) A two-week delay to make some minimal aesthetic improvements is hardly a great imposition being imposed on the developer.
(4) If the developer would rather build a crappy building elsewhere with their own money, then they are welcome to pick up and do so.
(4) Indianapolis is a major city, not some podunk town that needs to spread its legs for any developer that throws the place a sideways glance. Indianapolis should insist on the best, not settle for junk. Accepting anything is not going to make Indianapolis grow any faster (not sure where you got that silly notion from), nor is Indianapolis a slow-growth city compared to similarly sized city's in the Midwest.
Alone. Or with cheese.